| Bid | 7.5 |
| Market Cap | 385.63M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.73 |
| PE Ratio (ttm) | -4.46 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.02 |
| Volume | 58,281 |
| Avg. Volume (20D) | 214,937 |
| Open | 7.79 |
| Previous Close | 7.56 |
| Day's Range | 7.59 - 7.90 |
| 52-Week Range | 6.63 - 12.38 |
| Beta | undefined |
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was inc...
Analyst Forecast
According to 4 analyst ratings, the average rating for AURA stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 197.93% from the latest price.
2 months ago · seekingalpha.com
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder ValueThe positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is ex...
